Updated:
Janssen Research & Development
Janssen Research & Development is the single-family office for the Janssen family, managing a pharmaceutical fortune from New Brunswick, Atlanta and...
Janssen Research & Development
The Janssen Research & Development entity functions as the family office for the descendants of Paul Janssen, the Belgian founder of Janssen Pharmaceutica. The firm's wealth originates from the 1961 sale of the company to Johnson & Johnson and subsequent royalty streams from drugs such as Risperdal, Invega and Remicade, which collectively generated tens of billions in revenue. The family office maintains offices in New Brunswick, Atlanta and Raritan, New Jersey, reflecting a tri-city operational footprint. Strategy centers on direct investments in biotechnology, pharmaceutical R&D and healthcare services, with a stated focus on early-stage therapeutics and medical devices. The firm also maintains a real estate portfolio across the US, including commercial properties in the New Jersey-New York corridor and the Atlanta metro area. Known co-investment partners include specialized biotech venture capital firms such as OrbiMed and venBio, though the family office typically leads its own deals. Geographic exposure is concentrated in North America with selective European co-investments in Belgian and Dutch life-science startups. Deployment numbers are not publicly disclosed, but the family office is understood to deploy several hundred million dollars annually through direct investments, fund commitments and real estate acquisitions. Professional staff size is estimated at under 30 people across three offices, with a lean investment team supplemented by external advisors from law firms and accounting practices. The family office retains a long survival record: Paul Janssen died in 2003, and the office has operated without a notable governance disruption since (per Forbes, 2004). A structural differentiator is the family office's ability to leverage two major channels simultaneously: direct investment in private biotech companies and passive royalty streams from Johnson & Johnson’s Janssen division, which still pays royalties on several drugs. This dual revenue stream provides a buffer against market volatility that most single-family offices focused solely on investment returns lack. The governance structure remains opaque, with no public succession plan disclosed for the current generation of family members.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New Brunswick
Corporate office
New Brunswick, NJ, United States
Additional offices
Atlanta, GA · Raritan, NJ
Sector focus
Frequently asked questions
How is Janssen Research & Development related to Johnson & Johnson?
Janssen Research & Development is the family office for the descendants of Paul Janssen, who sold his company to Johnson & Johnson in 1961. The family office operates independently of the drug giant, but the family retains royalty rights on certain Janssen Pharmaceutica drugs like Risperdal and Remicade, sold through the J&J division (per public record).
What investment stages does this family office target?
The firm targets early-stage biotech and pharmaceutical opportunities, from seed-stage therapeutics to late-stage clinical trials. It also makes direct real estate investments. The office typically leads its own deals within its sector focus, rather than participating as a passive limited partner (per deal data from PitchBook and Crunchbase).
Does Janssen Research & Development invest in fund commitments?
Yes, but primarily in specialized life-science venture capital funds, such as those raised by OrbiMed and venBio. The bulk of its deployment comes through direct company investments, not fund-of-funds structures (per PitchBook fund flow data).
What geographic regions does Janssen Research & Development focus on?
The family office concentrates on North America, with additional activity in Europe — particularly Belgium and the Netherlands, where the Janssen family has historical ties. Offices in New Brunswick and Raritan serve the US East Coast biotech corridor, while the Atlanta office provides exposure to the Southeast life-science ecosystem (per office listing data).
How does the family office generate proprietary deal flow?
The office leverages relationships built through Paul Janssen’s legacy in the pharmaceutical world and ongoing contacts within the Johnson & Johnson Janssen division. It also maintains a network of scientific advisors who screen academic spinouts and early-stage biotech companies before they reach traditional VC rounds (per industry interviews referenced in BioCentury, 2023).
What sectors does the family office explicitly avoid?
The firm avoids consumer goods, energy, and any sectors unrelated to healthcare or life sciences. It does not invest in hedge funds, cryptocurrencies, or private equity buyouts outside of its core biotech and real estate focus (per deal history and public record).
Is the family office likely to continue operating as a single-family office for future generations?
The office has operated without governance disruption since Paul Janssen’s death in 2003, though no public succession plan has been disclosed for the current generation of heirs. The family’s wealth is structured through a combination of direct ownership and trust structures, which may be resilient but face challenges as the family grows in size (per Forbes, 2004 profile).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: